METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE-SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Chemo plus hormone therapy boosts survival in advanced prostate cancer
Disease control CompletedThis study tested whether adding chemotherapy (docetaxel) to standard hormone therapy helps men with metastatic prostate cancer live longer. About 790 men took part. Results showed that the combination improved overall survival compared to hormone therapy alone.
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
New combo therapy for advanced prostate cancer shows promise in large trial
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. Over 1,200 men participated in this phase 3 trial. The st…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 26, 2026 03:12 UTC
-
New drug combo slows advanced prostate cancer in major trial
Disease control CompletedThis study tested whether adding enzalutamide to standard hormone therapy (ADT) helps men with prostate cancer that has spread to other parts of the body. About 1,150 men took part. The goal was to see if the combination delayed cancer growth on scans and improved survival. Resul…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated May 26, 2026 02:47 UTC
-
Promising prostate cancer combo trial halted early
Disease control CompletedThis study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) could help men with metastatic hormone-sensitive prostate cancer live longer or delay cancer growth. The trial enrolled 186 Chinese men and was stopped early …
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
New drug combo extends life in advanced prostate cancer trial
Disease control CompletedThis study tested whether adding darolutamide to standard hormone therapy and chemotherapy helps men with metastatic prostate cancer that still responds to hormones. Over 1,300 men took part. The goal was to see if the combination improved overall survival. Results showed that da…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Bayer • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
New model uses PET scans to forecast prostate cancer therapy outcomes
Knowledge-focused CompletedThis study looked at 168 men with metastatic hormone-sensitive prostate cancer to see if a model using PSMA-PET scans and routine medical information could predict how well they would respond to standard first-line treatment. The researchers used existing scans and medical record…
Matched conditions: METASTATIC HORMONE-SENSITIVE PROSTATE CANCER
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated May 26, 2026 03:10 UTC